Sarepta Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sarepta Therapeutics generated cash of -$500,993,000, which is less than the previous year. Cash used in financing activities reached the amount of $125,004,000 last year. Net change in cash is therefore -$541,792,000.
Cash Flow
| 2014 | -128.53M | -159.03M | 104.15M |
|---|---|---|---|
| 2015 | -149.46M | 8.41M | 147.80M |
| 2016 | -245.82M | -90.19M | 378.12M |
| 2017 | -231.99M | -178.81M | 888.08M |
| 2018 | -388.66M | -370.48M | 530.15M |
| 2019 | -456.46M | 286.72M | 642.55M |
| 2020 | 107.46M | -121.72M | 682.32M |
| 2021 | -443.17M | 495.41M | 561.56M |
| 2022 | -325.34M | -1.04B | 232.50M |
| 2023 | -500.99M | -165.80M | 125.00M |
SRPT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 985.80M | 2.12B | 1.51B | 843.64M | 370.82M | 599.82M | 122.55M | 80.30M | 73.55M | 256.96M |
Operating activities | ||||||||||
Net income | -535.97M | -703.48M | -418.78M | -554.12M | -715.07M | -361.91M | -50.68M | -267.26M | -220.03M | -135.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 44.39M | 41.86M | 38.01M | 26.91M | 30.54M | 12.24M | 8.09M | 5.61M | 5.24M | 3.69M |
Stock-based compensation expense | 182.51M | 233.01M | 113.94M | 108.07M | 78.60M | 0 | 30.46M | 29.96M | 32.11M | 20.34M |
| Deferred income tax benefit | 182.51M | 233.01M | 113.94M | 108.07M | 78.60M | 0 | 30.46M | 29.96M | 32.11M | 20.34M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -185.69M | -61.63M | -51.65M | -10.46M | -41.83M | -19.57M | -24.24M | -1.25M | -1.56M | 1.11M |
Inventories | -147.71M | -50.78M | -83.77M | -60.58M | -45.93M | -41.84M | -70.79M | -12.81M | -147M | -244.94M |
Accounts payable | -50.13M | 147.57M | 23.29M | 41.99M | 122.97M | 90.16M | 12.92M | 7.30M | 18.29M | 10.76M |
Cash generated by operating activities | -500.99M | -325.34M | -443.17M | 107.46M | -456.46M | -388.66M | -231.99M | -245.82M | -149.46M | -128.53M |
Investing activities | ||||||||||
Purchases Of Investments | -2.04B | -1.93B | -29.98M | -1.33B | -1.19B | -1.17B | -589.52M | -195.42M | -172.69M | -274.36M |
Investments In Property Plant And Equipment | -76.10M | -30.82M | -38.49M | -82.20M | -62.71M | -64.34M | -21.21M | -6.86M | -4.83M | -26.82M |
Acquisitions Net | 0 | 0 | 0 | 0 | -172.55M | 3.18M | -9.21M | 1.52M | 1.43M | 1.38M |
Cash generated by investing activities | -165.80M | -1.04B | 495.41M | -121.72M | 286.72M | -370.48M | -178.81M | -90.19M | 8.41M | -159.03M |
Financing activities | ||||||||||
Common Stock Issued | 51.24M | 30.04M | 548.53M | 312.05M | 365.35M | 513.40M | 353.95M | 364.80M | 119.91M | 104.24M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -7.76M | -4.79M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 304.16M | 0 | -291.11M | 245.62M | -267.21M | 584.95M | -7.60M | 17.40M | -94K |
Cash used in financing activities | 125.00M | 232.50M | 561.56M | 682.32M | 642.55M | 530.15M | 888.08M | 378.12M | 147.80M | 104.15M |
Net Change In Cash | -541.79M | -1.13B | 613.81M | 668.06M | 472.81M | -228.99M | 477.27M | 42.11M | 6.75M | -183.41M |
Cash at end of period | 444.00M | 985.80M | 2.12B | 1.51B | 843.64M | 370.82M | 599.82M | 122.42M | 80.30M | 73.55M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |